~$180–200B
US medical device market 2026
~40%
Share of global device market
6,500+
US device manufacturers
~90 days
Median FDA 510(k) review
USA Medical Device Market Overview
The USA is the world's largest medical device market — approximately US$180–200 billion in 2026, around 40% of global revenue — and home to most of the industry's giants: Medtronic (operational HQ), Johnson & Johnson MedTech, Abbott, Stryker, Boston Scientific, BD, Baxter, GE HealthCare, Edwards, Zimmer Biomet, and Intuitive Surgical.
The FDA's CDRH clears moderate-risk devices through 510(k) (median ~90 days), approves high-risk devices via PMA, and offers De Novo and Breakthrough Device pathways for novel technology. Post-clearance, the commercial gauntlet runs through CMS coding/coverage/payment, GPO national contracts (Vizient, Premier, HealthTrust), and hospital IDN value-analysis committees.
Structural trends — ambulatory surgery center migration, robotics platforms, continuous monitoring/CGM, and AI-enabled diagnostics — are redrawing category boundaries, while distributors (McKesson, Cardinal, Medline, Henry Schein) consolidate the supply chain.
Top Medical Device Companies in the USA
The following table lists the major medical device companies operating in the USA — including local manufacturers, multinational offices, regional players, and leading distributors.
| Company | HQ |
|---|---|
| Medtronic | USA / Ireland |
| Johnson & Johnson MedTech | USA |
| Abbott | USA |
| Stryker | USA |
| Boston Scientific | USA |
| BD (Becton Dickinson) | USA |
| GE HealthCare | USA |
| Baxter | USA |
| Edwards Lifesciences | USA |
| Zimmer Biomet | USA |
| Intuitive Surgical | USA |
| Dexcom | USA |
| ResMed | USA / Australia |
| Hologic | USA |
| Danaher (Beckman, Cepheid, Leica) | USA |
| Siemens Healthineers | Germany |
| Philips Healthcare | Netherlands |
| Fresenius Medical Care | Germany |
| McKesson Medical-Surgical | USA |
| Cardinal Health / Medline | USA |
Planning research in USA?
Primary research, market access & HEOR. Proposals within 48 hours.
BioNixus market research
Commission custom USA fieldwork
Book a 30-minute briefing to align on FDA pathway intelligence, stakeholder mapping, and competitive tracking for the USA.
List of Medical Device Companies in the USA by Category
USA medical device companies span local manufacturers, multinational corporation offices, regional suppliers, and key distributors.
Local Manufacturers
US-headquartered manufacturers dominate globally: Medtronic, J&J MedTech, Abbott, Stryker, Boston Scientific, BD, GE HealthCare, Baxter, Edwards, Zimmer Biomet, Intuitive, Dexcom, ResMed, Hologic, and Danaher.
- ✓ Medtronic
- ✓ Johnson & Johnson MedTech
- ✓ Abbott
- ✓ Stryker
- ✓ Boston Scientific
- ✓ BD (Becton Dickinson)
- ✓ GE HealthCare
- ✓ Baxter
- ✓ Edwards Lifesciences
- ✓ Zimmer Biomet
- ✓ Intuitive Surgical
- ✓ Dexcom
- ✓ ResMed
- ✓ Hologic
- ✓ Danaher (Beckman, Cepheid, Leica)
Multinational Offices
Foreign leaders — Siemens Healthineers, Philips, Fresenius — hold major US positions in imaging, monitoring, and dialysis.
- ✓ Siemens Healthineers
- ✓ Philips Healthcare
- ✓ Fresenius Medical Care
Regional Players
The US market is national-scale; "regional" players are specialist manufacturers feeding GPO and IDN niches.
Distributors
McKesson, Cardinal Health, Medline, Owens & Minor, and Henry Schein consolidate med-surg distribution to hospitals, ASCs, and physician offices.
- ✓ McKesson Medical-Surgical
- ✓ Cardinal Health / Medline
Medical Device Companies in the USA: FDA Regulatory Landscape
US Food and Drug Administration — CDRH is the USA's medical device regulator.
Regulatory Authority
US Food and Drug Administration — CDRH (FDA) oversees registration, quality control, pricing, vigilance, and import licensing.
Registration Timeline
510(k) ~90 days median; PMA 1–3 years; De Novo for novel moderate-risk
Renewal Period
Annual establishment registration
Pricing Model
Free market; CMS coding/coverage/payment and GPO/IDN contracts set effective prices
Key Registration Requirements
- ✓Establishment registration and device listing (FURLS)
- ✓510(k) substantial equivalence or PMA clinical evidence
- ✓QMSR (ISO 13485-harmonised) quality system
- ✓UDI labelling compliance
- ✓MDR adverse-event reporting
- ✓US Agent required for foreign manufacturers
Market Access Note
FDA clearance is necessary but not sufficient: commercial success requires CMS reimbursement strategy (codes, coverage, payment), GPO national agreements (Vizient, Premier, HealthTrust), and winning hospital value-analysis committee reviews. Breakthrough Device designation plus the TCET pathway can accelerate Medicare coverage for novel technology.
USA Medical Device Market Growth Drivers
ASC Migration
Procedures shifting to ambulatory surgery centers reshape ortho, cardio, and endoscopy purchasing economics.
Robotics & Digital Surgery
da Vinci 5, Mako, and new robotic entrants expand capital + per-procedure revenue models.
CGM & Connected Care
Dexcom/Libre expansion into type-2 and wellness populations creates the fastest-growing device category.
AI-Enabled Diagnostics
FDA-cleared AI imaging and pathology algorithms open software-as-device revenue streams.
Structural Heart Boom
TAVR, mitral/tricuspid, PFA electrophysiology, and Watchman expand interventional cardiology spend.
Aging & Chronic Burden
65+ population growth drives joint replacement, cardiac, and monitoring volume through the decade.
How BioNixus Supports Medical Device Companies in the USA
BioNixus is a healthcare market research company with primary-research capability in the USA and cross-market benchmarking against GCC, USA, and European markets. We help pharma, biotech, and medtech companies with:
Physician & Surgeon Research
IRB-compliant fieldwork with US surgeons, interventionalists, and clinicians across IDN, academic, and ASC settings.
Payer & Reimbursement Research
CMS and commercial payer coverage studies, coding pathway assessment, and value-dossier evidence.
VAC & Procurement Research
Value-analysis committee decision research and GPO/IDN contracting intelligence.
US vs Global Benchmarking
Comparative launch sequencing for medtech weighing the US against EU, Japan, and GCC entries.
Frequently Asked Questions
What are the top 10 medical device companies in the USA?
By 2026 revenue: Medtronic, Johnson & Johnson MedTech, Abbott, GE HealthCare, BD, Stryker, Boston Scientific, Baxter, Zimmer Biomet, and Edwards Lifesciences — with Intuitive Surgical, Dexcom, Hologic, and Danaher's diagnostics group close behind.
What is the size of the US medical device market?
The US medical device market is valued at approximately US$180–200 billion in 2026 — about 40% of the global market — growing 5–6% annually on procedure recovery, robotics, CGM, and structural heart expansion.
How does FDA device clearance work?
Moderate-risk (Class II) devices clear via 510(k) substantial equivalence (~90 days median). High-risk (Class III) devices require PMA with clinical trials (1–3 years). Novel moderate-risk devices use De Novo, and Breakthrough Device designation accelerates review and Medicare coverage discussions.
What are GPOs and why do they matter?
Group Purchasing Organizations — Vizient, Premier, HealthTrust — negotiate national contracts covering most US hospital purchasing. GPO agreement plus IDN value-analysis committee approval is the de facto route to hospital shelf space.
How does device reimbursement work in the USA?
Three layers: coding (CPT/HCPCS/ICD-10-PCS), coverage (CMS national/local determinations and commercial policies), and payment (DRG bundles, APC rates, physician fees). New technology can seek NTAP add-on payments and the TCET pathway for accelerated Medicare coverage.
Can foreign device companies sell directly in the USA?
Yes — foreign manufacturers register with FDA, appoint a US Agent, comply with QMSR/UDI, and typically enter via distributors or direct sales forces. Success depends on reimbursement strategy and GPO/IDN access more than regulatory clearance alone.
Data Sources & Methodology
This guide aggregates publicly available information from:
- FDA CDRH — 510(k), PMA, De Novo databases
- CMS coding and coverage determinations
- AdvaMed industry statistics
- Company filings (NYSE/NASDAQ-listed manufacturers)
- BioNixus proprietary research (USA, 2024–2026)
Company lists are editorial snapshots, not endorsements; market sizes are BioNixus estimate ranges synthesised from regulator and industry sources. For customised market intelligence on the USA, contact our team.